William Blair analyst Myles Minter has maintained their neutral stance on MRNA stock, giving a Hold rating on August 19.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myles Minter’s rating is based on the recent approval of Moderna’s updated COVID-19 vaccines targeting the LP.8.1 variant, which aligns with the FDA’s guidance for the 2025-2026 season. The approval includes both Moderna’s first-generation Spikevax and second-generation mNexspike vaccines. Despite potential political challenges, the FDA’s approval maintains focus on vaccinating individuals at high risk for severe COVID-19, as well as all individuals aged 65 and older.
Minter notes that the updated vaccine labels did not change the target populations for Spikevax and mNexspike, which were already expanded in July to include younger age groups and at-risk individuals. The requirement for further placebo-controlled efficacy studies for broader approval suggests a cautious approach to expanding the vaccine’s use. These factors contribute to Minter’s Hold rating, reflecting a balanced view of Moderna’s current market position and regulatory landscape.
In another report released on August 19, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $28.00 price target.